BRPI0517132A - regime de cladribina para o tratamento da esclerose múltipla - Google Patents

regime de cladribina para o tratamento da esclerose múltipla

Info

Publication number
BRPI0517132A
BRPI0517132A BRPI0517132-6A BRPI0517132A BRPI0517132A BR PI0517132 A BRPI0517132 A BR PI0517132A BR PI0517132 A BRPI0517132 A BR PI0517132A BR PI0517132 A BRPI0517132 A BR PI0517132A
Authority
BR
Brazil
Prior art keywords
multiple sclerosis
treatment
cladribine
preparation
regimen
Prior art date
Application number
BRPI0517132-6A
Other languages
English (en)
Inventor
Giampiero De Luca
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0517132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Serono Lab filed Critical Serono Lab
Publication of BRPI0517132A publication Critical patent/BRPI0517132A/pt
Publication of BRPI0517132B1 publication Critical patent/BRPI0517132B1/pt
Publication of BRPI0517132B8 publication Critical patent/BRPI0517132B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

REGIME DE CLADRIBINA PARA O TRATAMENTO DA ESCLEROSE MúLTIPLA. Refere-se ao uso de Cladribina para o preparo de uma formulação farmacêutica para o tratamento da esclerose múltipla, especialmente a esclerose múltipla remitente-recorrente ou esclerose múltipla progressiva secundária prematura, caracterizado pelo fato de que o preparo deve ser oralmente administrado e caracterizado pelo fato de que novos tratamentos são possíveis.
BRPI0517132A 2004-12-22 2005-12-20 uso de cladribina para preparação de uma formulação farmacêutica para tratamento de esclerose múltipla BRPI0517132B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909.7 2004-12-22
EP04106909 2004-12-22
US60/638,669 2004-12-22
PCT/EP2005/056954 WO2006067141A1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (3)

Publication Number Publication Date
BRPI0517132A true BRPI0517132A (pt) 2008-09-30
BRPI0517132B1 BRPI0517132B1 (pt) 2020-02-18
BRPI0517132B8 BRPI0517132B8 (pt) 2021-05-25

Family

ID=36227798

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517132A BRPI0517132B8 (pt) 2004-12-22 2005-12-20 uso de cladribina para preparação de uma formulação farmacêutica para tratamento de esclerose múltipla

Country Status (25)

Country Link
US (2) US7713947B2 (pt)
EP (7) EP2275110B1 (pt)
JP (7) JP5795456B2 (pt)
KR (1) KR20070091662A (pt)
AR (1) AR052830A1 (pt)
AU (2) AU2005318190B2 (pt)
BR (1) BRPI0517132B8 (pt)
CA (2) CA2588966C (pt)
CY (3) CY1112614T1 (pt)
DK (3) DK3332789T3 (pt)
EA (1) EA015799B1 (pt)
ES (2) ES2921858T3 (pt)
FI (1) FI4070800T3 (pt)
FR (1) FR18C1008I2 (pt)
HR (1) HRP20120228T1 (pt)
HU (3) HUE059133T2 (pt)
IL (2) IL183930A0 (pt)
LT (3) LT3332789T (pt)
LU (1) LUC00064I2 (pt)
MX (1) MX2007007610A (pt)
NO (1) NO20073813L (pt)
PL (4) PL2805723T3 (pt)
SG (1) SG160391A1 (pt)
SI (3) SI2805723T1 (pt)
WO (1) WO2006067141A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2805723T3 (pl) 2004-12-22 2018-04-30 Merck Serono Sa Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego
MX2008014971A (es) * 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
AR113906A1 (es) * 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
IL301246A (en) 2020-09-10 2023-05-01 Merck Patent Gmbh Treatment regimen with cladribine
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
PL321431A1 (en) 1994-12-22 1997-12-08 Ortho Pharma Corp Soluble 2-chloro-2'deoxyadenosine compositions
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
WO2004028462A2 (en) 2002-09-25 2004-04-08 Brigham Young University, Technology Transfer Office Method for the preparation of 2-halo-2'-deoxyadenosine compounds from 2'-deoxyguanosine
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
BRPI0407781A (pt) * 2003-02-25 2006-02-14 Applied Research Systems aplicação combinada de ribavirina e interferon beta em doenças desmielinizantes
WO2004087101A2 (en) 2003-03-28 2004-10-14 Ivax Corporation Oral formulations of cladribine
ES2584183T3 (es) 2003-03-28 2016-09-26 Ares Trading S.A. Formulaciones de cladribina para suministro mejorado oral y transmucosa
PL2805723T3 (pl) 2004-12-22 2018-04-30 Merck Serono Sa Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego
MX2008014971A (es) * 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.

Also Published As

Publication number Publication date
CA2588966A1 (en) 2006-06-29
EP2263678A2 (en) 2010-12-22
CA3087419C (en) 2023-03-07
CA3087419A1 (en) 2006-06-29
EP3332789A1 (en) 2018-06-13
EP4523753A2 (en) 2025-03-19
EP2805723A1 (en) 2014-11-26
ES3007339T3 (en) 2025-03-19
SI2805723T1 (en) 2018-02-28
LTPA2018503I1 (lt) 2018-03-12
LT4070800T (lt) 2025-01-10
JP2018165271A (ja) 2018-10-25
EP3332789B1 (en) 2022-04-06
AR052830A1 (es) 2007-04-04
BRPI0517132B1 (pt) 2020-02-18
KR20070091662A (ko) 2007-09-11
DK2805723T3 (da) 2018-01-29
AU2005318190B2 (en) 2010-11-25
EP1827461A1 (en) 2007-09-05
EP4523753A3 (en) 2025-05-28
MX2007007610A (es) 2007-08-03
EP4070800A1 (en) 2022-10-12
JP2008524313A (ja) 2008-07-10
JP2020193206A (ja) 2020-12-03
EP1827461B1 (en) 2012-02-29
HUE070333T2 (hu) 2025-05-28
JP6430554B2 (ja) 2018-11-28
HUE059133T2 (hu) 2022-10-28
PL3332789T3 (pl) 2022-08-22
EA015799B1 (ru) 2011-12-30
JP2013216664A (ja) 2013-10-24
EP4070800B1 (en) 2024-10-16
JP6290962B2 (ja) 2018-03-07
AU2005318190A1 (en) 2006-06-29
BRPI0517132B8 (pt) 2021-05-25
SG160391A1 (en) 2010-04-29
PL2805723T3 (pl) 2018-04-30
FR18C1008I1 (pt) 2018-03-30
LT3332789T (lt) 2022-07-25
US20090081163A1 (en) 2009-03-26
JP2017101061A (ja) 2017-06-08
LTC2805723I2 (lt) 2022-04-25
FR18C1008I2 (fr) 2019-03-01
CY2018006I1 (el) 2018-06-27
LUC00064I2 (pt) 2018-03-28
HUS1800009I1 (hu) 2018-05-02
EP2263678B1 (en) 2014-06-11
NO20073813L (no) 2007-09-21
JP2015180685A (ja) 2015-10-15
CY2018006I2 (el) 2018-06-27
WO2006067141A1 (en) 2006-06-29
EP2275110A3 (en) 2011-04-27
IL212421A (en) 2014-01-30
EA200701221A1 (ru) 2008-02-28
FI4070800T3 (fi) 2025-01-14
CY1119790T1 (el) 2018-06-27
JP6092945B2 (ja) 2017-03-08
CY1112614T1 (el) 2016-02-10
AU2011200768B2 (en) 2012-09-13
JP2016138128A (ja) 2016-08-04
SI4070800T1 (sl) 2025-03-31
US7713947B2 (en) 2010-05-11
IL183930A0 (en) 2007-10-31
US20100203017A1 (en) 2010-08-12
PL4070800T3 (pl) 2025-03-10
PL1827461T3 (pl) 2012-07-31
ES2921858T3 (es) 2022-09-01
US8377903B2 (en) 2013-02-19
HRP20120228T1 (hr) 2012-04-30
EP2805723B1 (en) 2018-01-17
EP2275110B1 (en) 2013-07-10
JP5795456B2 (ja) 2015-10-14
IL212421A0 (en) 2011-06-30
JP5908863B2 (ja) 2016-04-26
SI3332789T1 (sl) 2022-08-31
LUC00064I1 (pt) 2018-02-14
AU2011200768A1 (en) 2011-03-17
EP2263678A3 (en) 2011-04-27
EP2275110A2 (en) 2011-01-19
CA2588966C (en) 2020-07-21
DK3332789T3 (da) 2022-07-11
DK4070800T3 (da) 2025-01-02

Similar Documents

Publication Publication Date Title
BRPI0622054B8 (pt) composto e composição farmacêutica
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
BRPI0706676B8 (pt) uso de uma solução aquosa com potencial de oxirredução
ECSP055525A (es) Inhibidores de cinasas de tirosina
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
WO2007068354A8 (en) Means and methods for the treatment of tumorous diseases
BRPI0409319B8 (pt) composto, composição farmacêutica, forma de dosagem unitária, e, uso de um composto
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
BR112014010417A2 (pt) Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina
BR112022008192A2 (pt) Queratina bd-4, sua preparação e composições farmacêuticas e uso
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
BRPI0519242A2 (pt) uso derivados de 1-aminociclohexano para o tratamento de esclerose méltipla, instabilidade emocional e paralisia pseudobulbar
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
BRPI0517132B8 (pt) uso de cladribina para preparação de uma formulação farmacêutica para tratamento de esclerose múltipla
BRPI0511420A (pt) fosforodiamidatos de sulfoniletila
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
BRPI0418726A (pt) naftalenossulfonato de clopidogrel cristalino ou hidrato do mesmo, método para sua preparação e composição farmacêutica contendo o mesmo
BRPI0519006A2 (pt) uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
BR0316021A (pt) Comibinação compreendendo um inibidor de cdk e cisplatina
BRPI0513825A (pt) combinações de epotilona
BR112022007632A2 (pt) Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer
CY1125491T1 (el) Δοσολογικο σχημα κλαδριβινης για τη θεραπεια της σκληρυνσης κατα πλακας
BRPI0510906A (pt) composição farmacêutica tópica, composição para administração tópica e seu uso

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SERONO S.A. (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.004954/2024-48 ORIGEM: 7A VARA FEDERAL CIVEL DA SJDF PROCESSO NO: 1120111-10.2023.4.01.3400 ACAO PELO PROCEDIMENTO COMUM AUTOR: MERCK SERONO S.A. REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI